Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions
COVID-19PharmacokineticsSafety
Interventions
DRUG

Q-Griffithsin

Q-Griffithsin is derived from Griffithsin (GRFT) which is a non-glycosylated protein consisting of 121 amino acids. Q-GRFT contains a single amino acid substitution, M78Q variant, resistant to oxidation yet maintains the parent molecule's pharmacological profile.

DRUG

Placebo

A matched vehicle solution manufactured and dispensed in same applicators as the active comparator.

Trial Locations (1)

15213

Ingrid Macio, Pittsburgh

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sharon Hillier

OTHER